Gelteq Pty Ltd

General Information
Business:

We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. (Incorporated in Australia)

A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — for pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent pending multiple-ingredient dosage forms, and that we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (“white label”). 

**Note: Revenue and net loss figures are in U.S. dollars (converted from Australian dollars) for the nine months that ended March 31, 2022.

(Note: Gelteq Ltd. filed its F-1 dated Aug. 30, 2022. The company filed confidential IPO documents on March 31, 2022.)

Industry: Pharmaceuticals
Employees: 3
Founded: 2018
Contact Information
Address Level 4 100 Albert Road South Melbourne VIC, 3025 Australia
Phone Number +61 3 9087 3990
Web Address http://www.gelteq.com
View Prospectus: Gelteq Pty Ltd
Financial Information
Market Cap $36.86mil
Revenues $0.09 mil (last 12 months)
Net Income $-1.46 mil (last 12 months)
IPO Profile
Symbol GELS
Exchange NASDAQ
Shares (millions): 1.3
Price range $5.00 - $5.00
Est. $ Volume $6.5 mil
Manager / Joint Managers Boustead Securities
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change